Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Change in Accured Expenses (2020 - 2026)

Design Therapeutics' Change in Accured Expenses history spans 2 years, with the latest figure at -$26000.0 for Q4 2021.

  • On a quarterly basis, Change in Accured Expenses fell 103.6% to -$26000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $2.4 million, a 69.09% increase, with the full-year FY2025 number at $4.5 million, up 468.01% from a year prior.
  • Change in Accured Expenses hit -$26000.0 in Q4 2021 for Design Therapeutics, down from $1.4 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for DSGN hit a ceiling of $2.0 million in Q2 2020 and a floor of -$1.8 million in Q1 2020.